Celyad Oncology SA — Proxy Solicitation & Information Statement 2023

Oct 27, 2023

CELYAD ONCOLOGY SA Listed limited liability company

Rue André Dumont 9 1435 Mont-Saint-Guibert

LER Nivelles 0891.118.115

(the "Company")

INFORMATION CONCERNING THE RIGHTS OF SHAREHOLDERS PURSUANT TO ARTICLES ARTICLE 7:130 OF THE CODE OF COMPANIES AND ASSOCIATIONS ON THE OCCASION OF THE EXTRAORDINARY MEETING OF THE COMPANY TO BE HELD ON 14 NOVEMBER 2023 AT 2 PM AT THE COMPANY'S REGISTERED OFFICE

1. RIGHT OF SHAREHOLDERS TO ASK WRITTEN QUESTIONS

Shareholders may ask questions exclusively in writing before the meeting, concerning the report of the board of directors or the agenda of the meeting. The Company will answer the questions during the meeting.

The exercise of this right is subject to the fulfilment of the following two conditions:

• being a shareholder of the Company on the record date (31 October 2023 at midnight (Belgian time)); and
• having informed the Company of the intent to participate in the general meeting, pursuant to the provisions set out in the convening notice.

The questions can be sent prior to the general meeting by email to the address investors@celyad.com or by mail marked for the attention of Celyad Oncology SA, Mrs. An Phan, Head of Legal, Rue André Dumont 9, B-1435 Mont-Saint-Guibert.

Those questions must be received by the Company on 8 November 2023 at 17h00 (CET) at the latest.

In accordance with applicable legal provisions, the directors answer questions that are asked by the shareholders during the meeting or that have been asked in writing prior to the meeting, during the general meeting on their report or on the agenda. The auditor also answers questions asked by the shareholders at the meeting or in writing prior to the meeting on its report.

Further information relating to the abovementioned right and the modalities for exercising them are available on the Company's website (www.celyad.com).